Trial Profile
An Open-Label Pilot Study of KPL-914 in Recurrent Pericarditis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Rilonacept (Primary)
- Indications Pericarditis
- Focus Proof of concept; Therapeutic Use
- Sponsors Kiniksa Pharmaceuticals
- 23 Nov 2020 Results published in the Heart
- 17 Nov 2020 Results assessing exploratory CMR data presented at the American Heart Association Scientific Sessions 2020
- 30 Mar 2020 Results (N=15), assessing corticosteroid tapering and discontinuation, presented at the 2020 Annual Scientific Session of the American College of Cardiology and World Congress of Cardiology